New drug trial targets rare cancer mutations
NCT ID NCT06400225
Summary
This trial is testing an oral drug called ulixertinib in patients with advanced cancers that have specific, less common changes in a gene called BRAF. The drug aims to block signals that tell cancer cells to grow, potentially slowing or stopping the disease. It is for patients with solid tumors, lymphoma, or multiple myeloma that have not responded to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.